Stockscreener 앱 받기
16.58
0.06%
0.010
시간 외 거래:
16.58
전일 마감가:
$16.57
열려 있는:
$16.54
하루 거래량:
2.34M
Relative Volume:
0.80
시가총액:
$52.39B
수익:
$29.91B
순이익/손실:
$1.30B
주가수익비율:
40.88
EPS:
0.4056
순현금흐름:
$3.49B
1주 성능:
+0.97%
1개월 성능:
-6.96%
6개월 성능:
+17.67%
1년 성능:
+16.51%
1일 변동 폭
$16.46
$16.66
1주일 범위
$15.98
$16.76
52주 변동 폭
$12.99
$18.89
다케다약품공업 ADR Stock (TAK) Company Profile
명칭
Takeda Pharmaceutical Co Adr
전화
-
주소
-
Compare TAK vs HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
16.58 | 52.36B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.20 | 40.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.63B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.92 | 32.58B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
566.80 | 24.07B | 3.17B | 1.29B | 1.01B | 27.09 |
다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-13 | 재개 | Morgan Stanley | Overweight |
| 2025-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-07-19 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-10-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 개시 | Cowen | Market Perform |
| 2019-08-15 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
모두보기
다케다약품공업 ADR 주식(TAK)의 최신 뉴스
Jury Hits Takeda With $885 Million Antitrust Verdict - Benzinga
Takeda Pharmaceutical stock (JP3730800003): earnings in focus as investors weigh legal risks - AD HOC NEWS
Takeda Pharmaceutical stock (JP3730800003): recent earnings and Rybelsus biosimilar plans in focus - AD HOC NEWS
Takeda Pharmaceutical Co Ltd stock (JP3730800003): earnings beat but softer EPS outlook - AD HOC NEWS
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline - Morningstar
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 By Investing.com - Investing.com Australia
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 - Investing.com
Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals - AD HOC NEWS
Takeda Pharma ADR earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Takeda Surpasses Earnings Estimates Despite Revenue Miss - HarianBasis.co
What's Going On With Takeda Stock Wednesday?Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga
Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience - Investing.com
Takeda Pharmaceutical stock (JP3730800003): Q4 2026 earnings report released - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd stock (JP3730800003): Is its rare disease focus strong enough to unlock - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock News, Headlines & Updates - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Baskets - GuruFocus
Takeda Pharmaceutical (ADR) stock (US8740602052): Why Google Discover changes matter more now - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Competitors 2026 - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Operating Data - GuruFocus
Takeda Pharmaceutical Co Ltd stock: What you should know now for smart investing - AD HOC NEWS
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Benzinga
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Takeda Pharmaceutical (ADR) Stock: A Stable Global Pharma Play with Focus on Oncology and Rare Disea - AD HOC NEWS
Who's Buying or Selling Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock Today? - gurufocus.com
Takeda Pharmaceutical Co Ltd Stock Intrinsic Values | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Historical Valuations | HAM:TKDA - GuruFocus
Takeda Pharmaceutical Co Ltd (LTS:0A87) Bonds - GuruFocus
Takeda Pharmaceutical stock faces pressure from geopolitical risks amid pipeline advances - AD HOC NEWS
Takeda Pharmaceutical (ADR) stock faces pressure amid pipeline setbacks and competitive oncology cha - AD HOC NEWS
Takeda: 'Hold' Despite Performance In 2025-2026 (NYSE:TAK) - Seeking Alpha
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
다케다약품공업 ADR (TAK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.03%
자본화:
|
볼륨(24시간):